Illumina completes acquisition of SomaLogic
MWN-AI** Summary
Illumina, Inc. has successfully finalized its acquisition of SomaLogic, a key player in data-driven proteomics technology, for approximately $350 million in cash, with potential additional performance-based payments that could total $75 million. This acquisition marks a significant advancement in Illumina's strategy to enhance its multiomics portfolio, particularly in the growing field of proteomics, a branch of science focused on the study of proteins and their functions.
The integration of SomaLogic's innovative proteomics capabilities with Illumina's extensive Next-Generation Sequencing (NGS) ecosystem—featuring products like DRAGEN software and Illumina Connected Multiomics—aims to accelerate drug discovery processes and improve healthcare outcomes. Jacob Thaysen, CEO of Illumina, emphasized that this combination will provide scalable insights across both genomics and proteomics, significantly enhancing customer access to crucial biological data.
SomaLogic's technologies, especially the SomaScan platform, are designed to offer deep insights into protein functionalities and interactions, fostering a better understanding of complex biological systems. With this acquisition, Illumina intends to leverage its market reach and product innovation to build scalable growth opportunities within the expanding proteomics sector.
Illumina has previously collaborated with SomaLogic since 2021, working together to integrate SomaLogic’s proteomics assay into Illumina’s NGS platforms. The completed acquisition aims to further strengthen this partnership while ensuring a smooth transition for SomaLogic's customers and existing collaborations. As Illumina continues to integrate SomaLogic’s offerings, the company remains committed to supporting all partners involved and enhancing the overall value presented in the proteomics market.
MWN-AI** Analysis
Illumina's recent acquisition of SomaLogic signifies a pivotal moment in the biotechnological landscape, enhancing Illumina's capabilities in the growing proteomics sector. This strategic move complements their existing genomics portfolio, enabling a more robust multiomics approach that combines DNA sequencing with comprehensive protein analysis, thereby positioning Illumina as a leader in integrated health solutions.
The acquisition, completed at a total valuation of approximately $425 million, reflects Illumina’s commitment to scaling their technology offerings and expanding their market reach. By integrating SomaLogic's advanced proteomics technology with its high-throughput sequencing systems and DRAGEN software, Illumina aims to streamline insights from complex biological data, facilitating faster drug discovery and improving patient outcomes.
Investors should note several key factors following this acquisition. Firstly, the growing demand for multiomics data, as researchers and clinicians seek comprehensive insights for precision medicine, presents a substantial opportunity for revenue growth. Illumina’s historical performance indicates a strong market position, and this acquisition likely enhances their competitive edge against other players like Roche and Thermo Fisher.
However, potential risks exist, including the challenges associated with integrating SomaLogic's technologies and ensuring seamless operational continuity for existing customers. The company's ability to manage these integration efforts effectively will be crucial for maintaining market confidence.
In summary, while Illumina represents an attractive investment given its leading innovations and strategic acquisitions, market participants should stay vigilant regarding integration progress and overall market dynamics. Monitoring Illumina’s upcoming earnings call on February 5, 2026, will provide additional insights into the financial implications of the SomaLogic acquisition and customer response to the newly integrated offerings. Adjusting expectations and positioning in response to these developments could be prudent for investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Deeply expands leadership in proteomics and multiomics
Combined capabilities bring high scalability, flexibility, and affordability into protein analysis
Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries
SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.
"Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024," said Jacob Thaysen, chief executive officer of Illumina. "By combining SomaLogic's highly differentiated proteomics technology with Illumina's industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients."
SomaLogic's technologies provide deep insights into protein function, interactions, and modifications, helping to accelerate understanding of complex biology and human health. Customers will benefit from the combined power of SomaScan, Illumina Protein Prep, SomaSignal Tests, DRAGEN software, and Illumina Connected Multiomics to generate rich multiomic datasets at scale, with the flexibility to adopt the tools and workflows that best match their needs.
Illumina is building new, scalable growth businesses that complement and accelerate its high-throughput sequencing franchise. The SomaLogic acquisition ideally positions Illumina for growth in the expanding proteomics market by increasing customer access to SomaLogic's technologies and service offerings, coupled with Illumina's product innovation and global market reach.
Illumina remains an open, accessible, and enabling next-generation sequencing (NGS) platform, and will work closely with customers to provide continuity of products, services, and support as SomaLogic's portfolio is integrated into Illumina's product and solutions roadmap.
Illumina and SomaLogic have partnered in proteomics co-development since late 2021, when the companies entered into an agreement to bring the SomaScan Proteomics Assay onto Illumina's high-throughput NGS platforms. The completed acquisition builds on this foundation, expanding Illumina's presence in the large and growing proteomics market and advancing its leadership in multiomics. The company will continue to support SomaLogic customers and partnerships, including existing service providers using SomaLogic's array-based readout.
Illumina acquired SomaLogic and other specified assets from Standard BioTools for $350 million, subject to customary adjustments, in cash paid at closing, plus up to $75 million in near-term performance-based milestones and performance-based royalties. The deal was funded with cash on hand, and Illumina will discuss the financial implications of the transaction in our upcoming earnings call scheduled for February 5, 2026.
To learn more, visit https://www.illumina.com/company/news-center/somalogic-acquisition.html.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) the future conduct and growth of the business and the markets in which we operate, including the proteomics market; (ii) the success of products and services competitive with our own; (iii) our ability to successfully integrate the SomaLogic business into our existing operations and the SomaLogic business's technology and products into our portfolio; (iv) our ability to sell the products and further develop the SomaLogic business's technology; (v) our ability to successfully manage partner and customer relationships in the proteomics market; (vi) our ability to manufacture robust instrumentation and consumables including the SomaLogic business's products; (vii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; and (viii) customer uptake of, and satisfaction with, new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
SOURCE Illumina, Inc.
FAQ**
How does the acquisition of SomaLogic by Illumina Inc. ILMN enhance its capabilities in the rapidly growing proteomics market and what specific benefits can customers expect from this integration?
What are the anticipated financial implications of the SomaLogic acquisition for Illumina Inc. ILMN, including any expected impacts on revenue and growth in the multiomics sector?
Given Illumina’s existing partnership with SomaLogic since 2021, how will this acquisition streamline their efforts in co-developing proteomics technology on high-throughput NGS platforms?
What strategies will Illumina Inc. ILMN implement to ensure the successful integration of SomaLogic's technologies and customer relationships while minimizing potential risks associated with this acquisition?
**MWN-AI FAQ is based on asking OpenAI questions about Illumina Inc. (NASDAQ: ILMN).
NASDAQ: ILMN
ILMN Trading
-2.21% G/L:
$118.26 Last:
830,822 Volume:
$120.27 Open:
